| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| GDNF | HOT GMP-GDFH17 | GMP Human GDNF Protein (E. coli) | Human | E. coli | ![]() | MSSDS-PAGE | $700.00 50ug | |
| GDNF | Human GDNF / ATF / hGDNF Protein (E. coli), premium grade | Human | E. coli | ![]() | SDS-PAGE | $270.00 20ug | ||
| GDNF | Human GDNF / ATF / hGDNF Protein (E. coli), Research Grade | Human | E. coli | ![]() | SDS-PAGE | $200.00 20ug | ||
| GDNF | Human GDNF / ATF / hGDNF Protein, premium grade | Human | HEK293 | ![]() | SDS-PAGE | $245.00 20ug | ||
| GDNF | Mouse GDNF / ATF Protein, His Tag, low endotoxin (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $205.00 20ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| AB-1005 | AMT-140; AB-1005; AAV2-GDNF; AAV2-GDNF-MSA; AAV2-GDNF-PD | Phase 2 Clinical | Uc San Francisco | Multiple System Atrophy; Parkinson Disease | 상세 |
| NRO-1 | NRO-1; SI-01 | Phase 2 Clinical | Senju Pharmaceutical Co Ltd | Xerophthalmia | 상세 |
| Ifezuntirgene inilparvovec | AAV5-miSNP15; AMT-130; AAV5-miHtt12; AAV5-miSNP7 | Phase 2 Clinical | Amsterdam Molecular Therapeutics, Uniqure | Huntington Disease | 상세 |
| AAV2-GDNF gene therapy (NINDS) | Phase 1 Clinical | National Institute Of Neurological Disorders And Stroke | Parkinson Disease | 상세 | |
| RGL-193 | RGL-193 | Phase 1 Clinical | Shanghai Regenelead Therapies Co Ltd | Parkinson Disease | 상세 |
